TMCnet News
Cellular Dynamics signs agreement with ViaCyteApr 14, 2011 (Datamonitor Financial Deals Tracker via COMTEX) -- Cellular Dynamics International, Inc. (CDI), a developer of tools and services for drug discovery, screening and predictive toxicology, has signed an agreement with ViaCyte, Inc. (formerly Novocell, Inc.), a stem cell engineering company. Both the entities are based in the US. Under the partnership, CDI will strengthen its intellectual property (IP) portfolio by licensing patented definitive endoderm differentiation technology from ViaCyte. CDI will apply this patented methodology in the development and production of iCell(R) Hepatocytes, iPSC-derived liver cells. ViaCyte's proprietary technology covers cell cultures containing specific amounts of definitive endoderm. Definitive endoderm gives rise to organs and tissues such as the liver, pancreas, lung, intestine, thymus and thyroid. In addition, CDI has agreed to supply iPSC lines to ViaCyte. Deal Type Partnership Sub-Category Licensing Agreement,Supply Deal Status Announced: 2011-04-13 Deal Participants Partner 1 (Company) Cellular Dynamics International, Inc. Partner 2 (Company) Novocell, Inc. |